Exogenous HMGN2 inhibits the migration and invasion of osteosarcoma cell lines

Among the most prevalent forms of malignant tumors seen in children and teenagers, osteosarcoma (OS) is a bone disease originating from mesenchymal stem cells (1,2). OS is characterized by early metastasis, and approximately 15–25% of patients have detectable lung metastases at the time of their diagnosis (3). Tumor resection and nonspecific combination chemotherapy are the preferred modes of treatment for OS patients (4,5). With the advances made in relation to primary tumor treatment, patients with the disease have seen a rise in their long-term survival rate (6); however, for patients with distant metastasis, the survival rate remains very low (7-9). It is essential to find new and more effective treatment targets for OS to improve the survival time of patients. Abnormal expression of high mobility group nucleosome binding domain 2 (HMGN2) is associated with multiple tumors (10,11). HMGN2 takes on a key role in breast cancer progression (12-14) and inhibits the growth and Original Article